中国实验诊断学
中國實驗診斷學
중국실험진단학
CHINESE JOURNAL OF LABORATORY DIAGNOSIS
2015年
5期
735-739
,共5页
池细俤%高世华%陈家龙%李国玉%林蓉金
池細俤%高世華%陳傢龍%李國玉%林蓉金
지세제%고세화%진가룡%리국옥%림용금
鲍曼不动杆菌%多药耐药%基因型%耐药性
鮑曼不動桿菌%多藥耐藥%基因型%耐藥性
포만불동간균%다약내약%기인형%내약성
Acinetobacter baumannii%Multidrug-resistant%Genotype%Drugresistance
目的:研究多药耐药鲍曼不动杆菌(MDRAB)的耐药机制,为临床有效治疗该菌感染提供依据。方法应用 PCR 技术对94株 MDRAB 进行耐药基因检测,比较8种耐药基因阳性组与阴性组菌株的耐药性。结果耐药基因检出率:VIM 35.1%、SIM 55.0%、TEM 59.6%、OXA-2393.6%、OXA-2452.1%、SHV 52.1%、PER-183.0%、IMP 2.1%;仅 IPM、MEM、SAM 在 OXA-23基因阳性组与阴性组间,和 SAM 在 SIM 基因阳性组与阴性组间的耐药性有显著差异。结论 MDRAB 耐药基因检测不能代替常规药敏试验,无法预测临床治疗效果;MH、PO 仍为治疗MDRAB 的较好选择。
目的:研究多藥耐藥鮑曼不動桿菌(MDRAB)的耐藥機製,為臨床有效治療該菌感染提供依據。方法應用 PCR 技術對94株 MDRAB 進行耐藥基因檢測,比較8種耐藥基因暘性組與陰性組菌株的耐藥性。結果耐藥基因檢齣率:VIM 35.1%、SIM 55.0%、TEM 59.6%、OXA-2393.6%、OXA-2452.1%、SHV 52.1%、PER-183.0%、IMP 2.1%;僅 IPM、MEM、SAM 在 OXA-23基因暘性組與陰性組間,和 SAM 在 SIM 基因暘性組與陰性組間的耐藥性有顯著差異。結論 MDRAB 耐藥基因檢測不能代替常規藥敏試驗,無法預測臨床治療效果;MH、PO 仍為治療MDRAB 的較好選擇。
목적:연구다약내약포만불동간균(MDRAB)적내약궤제,위림상유효치료해균감염제공의거。방법응용 PCR 기술대94주 MDRAB 진행내약기인검측,비교8충내약기인양성조여음성조균주적내약성。결과내약기인검출솔:VIM 35.1%、SIM 55.0%、TEM 59.6%、OXA-2393.6%、OXA-2452.1%、SHV 52.1%、PER-183.0%、IMP 2.1%;부 IPM、MEM、SAM 재 OXA-23기인양성조여음성조간,화 SAM 재 SIM 기인양성조여음성조간적내약성유현저차이。결론 MDRAB 내약기인검측불능대체상규약민시험,무법예측림상치료효과;MH、PO 잉위치료MDRAB 적교호선택。
Objective OBJECTIVE To investigate the drug-resistant mechanism of Multi-drug Acinetobacter Bau-mannii (MDRAB),thus providing a theoretical basis for the effective treatment of MDRAB in clinical.Methods Drug-resistant gene sequencings for 94 MDRAB were made by Polymerase Chain Reaction (PCR).Drug resistances were contrasted between positive group and the negative group of 8 drug resistance genes of MDRAB.Results The detection rates of 8 drug resistance genes were VIM 35.1%,SIM 55.0%,TEM 59.6%,OXA-23 93.6%,OXA-24 52.1%,SHV 52.1%,PER-1 83.0%,IMP 2.1%.Drug resistance of Imipenem (IPM),meropenem (MEM),Ampicillin/Sulbactam (SAM)were only found to be significantly different between the positive group and negative group of OXA-23 gene. And drug resistance of SAM was only found to be significantly different between the positive group and negative group of SIM gene.Conclusion This study revealed that drug-resistant gene sequencing of MDRAB could not replace the nor-mal drug susceptibility testing,for its unpredictable clinical therapeutic effect.Besides,Minocycline (MH)and Poly-myxin B (PO)were still the better treatment in MDRAB.